Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
18,654
datasets available to search
ShareScore release 0.9.0
Dataset results
18,654 results for “Pain”
The causal role of the somatosensory cortex in prosocial behavior - Pain Localizer
<p>Participants with no reported neurological, psychiatric, or other medical problems or any contraindication to fMRI, underwent a total of 40 electrical and 40 mechanical stimulations, split in 8 runs (4 electrical and 4 mechanical) of 10 (5 high intensity and 5 low intensity) stimulations each on their right hand. For more information about task please refer to the pubblication. See the associated readme file for more details.</p> <p> </p>
Julio-Yanes/Yanes_Cannabis_MetaAnalysis: Effects of Cannabinoid Administration for Pain: A Meta-Analysis and Meta-Regression
<p>% The following codes are associated with...</p> <p>% Effects of Cannabinoid Administration for Pain: A Meta-Analysis and Meta-Regression... Yanes, J.A., McKinnell Z.E., Reid, M.A., Busler, J.N.,... ... Michel, J.S., Pangelinan, M.M., Sutherland, M.T., Younger, J.W... ... Gonzalez, R., and Robinson, J.L. (in press). Experimental % Clinical Psychopharmacology.</p> <p>% The following codes load data associated with the above mentioned manuscript, run analyses, and prepare tables/figures.</p> <p>% Catgorical data within the dataset were coded as follows... ... Design (0 = crossover, 1 = parallel). ... Treatment (0 = placebo, 1 = THC, 2 = THC/CBD extract [Sativex],... ... 3 = THC/CBD, 4 = Nabilone, 5 = Dronabinol, 6 = CT3, 7 = CBD). ... Treatment Collapsed (0 = placebo, 1 = cannabis [whole-plant,... ... extract], 2 = synthetic cannabinoid). ... Treatment Binary (0 = placebo, 1 = cannabinoid). ... Diagonsis (1 = abdominal pain, 2 = arthritis, 3 = cancer,... ... 4 = chronic pain, 5 = diabetes, 6 = fibromyalgia, 7 = HIV,... ... 8 = headache, 9 = "various", 10 = multiple sclerosis,... ... 11 = neuropathic pain, 12 = post-operative pain).</p>
Fibroblast-derived PI16 as a novel regulator of neuropathic pain
<p>Non-neuronal cells, including glia and leukocytes contribute to chronic pain. Here we identify fibroblasts secreting the protein PI16 as novel regulator of neuropathic pain. Mice deficient in PI16, a member of the CAP superfamily of proteases, are protected against neuropathic pain induced by spared nerve injury (SNI) or paclitaxel. SNI increases PI16 in fibroblasts and in vitro myofiborblast differentiation increases PI16 expression and secretion. In vitro, PI16 conditioned medium promotes migration of immune cells across the endothelial layer. Consistently, protection against neuropathic pain in PI16-/- mice was associated with reduced endothelial barrier permeability, lower leukocyte infiltration and reduced activation of the endothelial barrier regulator MLCK. Collectively our findings indicate that the fibroblast- derived protein PI16 promotes neuropathic pain by increasing vascular permeability and cellular infiltration. Due to its key role in pain and limited cellular distribution PI16 is an attractive novel target for pain management.</p>
Role of supraspinal sphingosine-1-phosphate receptor 1 in neuropathic pain
<p><span>An unbiased transcriptomic analysis of the RVM was used to identify genes affected by nerve injury and the impact of S1PR1 antagonism. </span></p>
Unravelling pain in Göttingen Minipigs undergoing experimentally induced closed-chest myocardial infarction.
<p>This file contains mechanical and thermal pain thresholds recorded in adult Göttingen Minipigs before and after experimentally induced myocardial infarction. </p> <p>Mechanical thresholds were recorded with a manual algometer (tip size 1 cm2); thermal thresholds consisted in heat contact stimuli. Thresholds were recorded at different body sites, namely: LC: left chest; RC: right chest; LF: left forearm; RF: right forearm; LN: left neck; RN: right neck. </p> <p>The Excel file also provides demographic data, physiological parameters (heart rate and respiratory rate), biomarkers (troponin I and cytokines), and feasibility scores. </p> <p> </p>
Pain coping strategies and their association with quality of life in people with Parkinson's Disease: a Cross-Sectional study
<p><b>Design</b> Cross-sectional, cohort study.</p> <p><b>Setting</b> Monocentric, inpatient, university hospital.</p> <p><b>Participants</b> 52 patients with Parkinson's disease (without dementia) analysed.</p> <p><b>Primary and secondary outcome measures</b> Motor function, nonmotor symptoms, health-related quality of life (QoL), and the Coping Strategies Questionnaire were assessed.</p>
Ediacara growing pains: Modular addition and development in Dickinsonia costata
Constraining patterns of growth using directly observable and quantifiable characteristics can reveal a wealth of information regarding the biology of the Ediacara Biota – the oldest macroscopic, complex community forming organisms in the fossil record. However, these rely on individuals captured at an instant in time at various growth stages, and so different interpretations can be derived from the same material. Here we leverage newly discovered and well-preserved <i>Dickinsonia costata</i> Sprigg 1947 from South Australia, combined with hundreds of previously described specimens, to test competing hypotheses for the location of module addition. We find considerable variation in the relationship between the total number of modules and body size that cannot be explained solely by expansion and contraction of individuals. Patterns derived assuming new modules differentiated at the anterior result in numerous examples where the oldest module(s) must decrease in size with overall growth, potentially falsifying this hypothesis. Observed polarity as well as the consistent posterior location of defects and indentations support module formation at this end in <i>D. costata</i>. Regardless, changes in repeated units with growth share similarities with those regulated by morphogen gradients in metazoans today, suggesting that these genetic pathways were operating in Ediacaran animals.
FAAH inhibition in migraine pain
<p>This dataset comprises the findings obtained in the study aimed at investigating the relevance of fatty-acid amide hydrolase (FAAH) inhibition in the nitroglycerin (NTG) animal model of migraine, by testing the effects of the globally active FAAH inhibitor URB597. The attention was focused on mapping neuronal c-Fos protein expression, measurement of anandamide (AEA) and palmitoylethanolamide (PEA) levels in brain areas and in trigeminal ganglia, evaluation of pain-related trigeminal behavior and quantification of molecular mediators in rats that received URB597 (2 mg/kg i.p.) either before or after NTG administration (10 mg/kg, i.p.).</p> <ol> <li>Evaluation of c-Fos expression by immunohistochemistry: cell counts of individual brain nuclei were made from every sixth section throughout their rostrocaudal extent for each rat. The nuclei evaluated were identified with the rat brain atlas Paxinos and Watson 4th edition. Trigeminal nucleus caudalis (TNC): from bregma −14.08 mm (interaural −5.08 mm) until −17 mm (interaural −8 mm); nucleus tractus solitarii (NTS): from bregma −13.24 mm (interaural −4.24 mm) until −13.68 mm (interaural −4.68 mm); locus ceruleus (LC): from bregma −9.80 mm (interaural −0.80 mm) until −10.04 mm (interaural −1.04 mm); parabrachial nucleus (PAB): from bregma −8.80 mm (interaural 0.20 mm) until −9.80 mm (interaural −0.50 mm); periaqueductal gray (PAG): from bregma −7.80 mm (interaural 1.20 mm) until −8.80 mm (interaural 0.20 mm).</li> <li>Measurement of AEA and PEA levels: medulla, cervical spinal cord and trigeminal ganglia were homogenized in cold methanol (2 ml) containing AEA-d4 and PEA-d4 as internal standards. After extraction the lipids were measured using a Xevo TQ UPLC-MS/MS system equipped with a reversed-phase BEH C18 column (2.1 × 50 mm, 1.7 μm particle size) (Waters, Milford, USA).</li> <li>Pain-related behavior in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–6 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</li> </ol> <p>mRNA expression levels: calcitonin gene-related peptide (CGRP), neuronal nitric oxide synthase (nNOS), interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-alpha) mRNA were evaluated in in medulla, cervical spinal cord and trigeminal ganglia; whereas, in dura mater were evaluated IL-1β and inducible NOS (iNOS). mRNA levels were measured by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</p>
Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study
<p>Simple Summary: Pain is one of the most common and debilitating symptoms in cancer patients. A clinical peculiarity of cancer pain is the breakthrough cancer pain (BTcP), which is defined as a temporary exacerbation of pain that “breaks through” a phase of adequate pain control by an opioid-based therapy. The NP-BTcP occurs in the absence of any specific activity. In this paper, we addressed the topic through a mathematical approach to provide many indications for identifying the diagnostic and therapeutic gaps in NP-BTcP management. Abstract: Breakthrough cancer pain (BTcP) is a temporary exacerbation of pain that “breaks through” a phase of adequate pain control by an opioid-based therapy. The non-predictable BTcP (NP-BTcP) is a subtype of BTcP that occurs in the absence of any specific activity. Since NP-BTcP has an important clinical impact, this analysis is aimed at characterizing the NP-BTcP phenomenon through a multidimensional statistical technique. This is a secondary analysis based on the Italian Oncologic Pain multiSetting—Multicentric Survey (IOPS-MS). A correlation analysis was performed to characterize the NP-BTcP profile about its intensity, number of episodes per day, and type. The multiple correspondence analysis (MCA) determined the identification of four groups (phenotypes). A univariate analysis was performed to assess differences between the four phenotypes and selected covariates. The four phenotypes represent the hierarchical classification according to the status of NP-BTcP: from the best (phenotype 1) to the worst (phenotype 4). The univariate analysis found a significant association between the onset time >10 min in the phenotype 1 (37.3%)’ vs. the onset > 10 min in phenotype 4 (25.8%) (p < 0.001). Phenotype 1 was characterized by the gastrointestinal type of cancer (26.4%) with respect to phenotype 4, where the most frequent cancer affected the lung (28.8%) (p < 0.001). Phenotype 4 was mainly managed with rapid-onset opioids, while in phenotype 1, many patients were treated with oral, subcutaneous, or intravenous morphine (56.4% and 44.4%, respectively; p = 0.008). The ability to characterize NP-BTcP can offer enormous benefits for the management of this serious aspect of cancer pain. Although requiring validation, this strategy can provide many indications for identifying the diagnostic and therapeutic gaps in NP-BTcP management.</p> <p> </p>
Traumatic events, post-traumatic stress disorder, and proxy measures for central sensitization in chronic pain patients of a German university outpatient pain clinic
<p>This dataset was acquired at Hannover Medical School, Hannover, Germany. The study complied with the Declaration of Helsinki, and was approved by the local ethics committee. All subjects gave written informed consent, and consent to use their data anonymously for research purposes. The study was registered at ClinicalTrials.gov (NCT05190367).</p> <p>Between February 2019 and July 2020, 914 patients who visited our outpatient pain department gave written consent to use their routinely collected data anonymously for research purposes. Participants were divided into four groups depending on their trauma severity: (1) no trauma; (2) accidental trauma (e.g. illness, accident, natural disaster); (3) interpersonal trauma (e.g. assault, rape, war); (4) PTSD (diagnosed according to ICD-10). Patients fulfilling two or more categories were assigned to the highest group.</p> <p>Data were collected using the SymptomMapper application [1]. Participants provided information about their traumas, current pain intensity (visual analogue scale, VAS (0-100) [2]), mean and maximal pain in the last 4 weeks (VAS (0-100)), sleep impairment (VAS (0-100)), acceptable pain (VAS (0-100)), pain disability index (PDI [3]), pain area (digital drawings), pain widespreadness (widespread pain index, WPI [4], derived from drawings), stress (patient health questionnaire, German version, PHQ-D [5]), anxiety (PHQ-D), depression (PHQ-D), and somatization symptoms (PHQ-D).</p> <p>This dataset contains the raw data as well as necessary scripts for reproducing the results of this study.</p> <p> </p> <p>References<br> ##########</p> <p>[1] Neubert TA, Dusch M, Karst M, Beissner F. Designing a Tablet-Based Software App for Mapping Bodily Symptoms: Usability Evaluation and Reproducibility Analysis. JMIR Mhealth Uhealth 2018;6(5):e127.<br> [2] Dworkin RH, Turk DC, Farrar JT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113(1):9-19.<br> [3] Pollard CA. Preliminary Validity Study of the Pain Disability Index. Percept Mot Skills 1984;59(3): 974.<br> [4] Wolfe F, Clauw DJ, Fitzcharles MA et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res 2010;62(5):600-10.<br> [5] Löwe B, Spitzer RL, Zipfel S, Herzog W. Gesundheitsfragebogen für Patienten (PHQ-D). Manual und Testunterlagen (second edition). Pfizer 2002.</p>
Pain et al. 2020 Behavioral and Physiological Responses to Instability in Group Membership in Wild Male Woolly Monkeys (Lagothrix lagotricha poeppigii)
<p>Data for Pain et al. 2020 Behavioral and Physiological Responses to Instability in Group Membership in Wild Male Woolly Monkeys (Lagothrix lagotricha poeppigii)</p>
How do patients sleep after orthopedic surgery? Changes in objective sleep parameters and pain in hospitalized patients undergoing hip and knee arthroplasty
<p><strong>Aim.</strong> Sleep impairment after hip and knee arthroplasty is multifactorial and still poorly understood and post-operative pain is a potential cause of sleep deprivation or disturbances. The aim of this study was to assess actigraphy-based sleep characteristics and pain scores in patients undergoing knee or hip joint replacement and hospitalized for ten days after surgery. <strong>Methods.</strong> In this observational cohort study, n=20 subjects (11 males and 9 females; age: 64.0±10.39 years old) completed a daily sleep diary and wore the Actiwatch 2 actigraph (Philips Respironics, Portland, OR) to record sleep parameters for 11 consecutive days, starting the day before surgery and ending the 10<sup>th</sup> day after surgery. Subjective scores of pain, by a visual analog scale (VAS), were constantly monitored for the entire experimental protocol. The following evaluation time-points have been considered for the analysis: pre-surgery (PRE), the first (POST1), the fourth (POST4) and the tenth day (POST10) after surgery. A repeated-measures one-way analysis of variance followed by the Tukey-Kramer post hoc tests, or the equivalent nonparametric Friedman test followed by the Dunn’s multiple comparisons, was applied to test differences in sleep and pain among time-points. Test for correlation between mean VAS score and the sleep parameters at each post-operative time point were performed using Pearson’s method. <strong>Results.</strong> Sleep quantity and timing parameters did not differ from PRE to POST10, during the hospitalization. On the contrary, Sleep Efficiency (p=0.006; η<sup>2</sup><sub>p</sub>=0.45, large), Sleep Latency (p=0.039; η<sup>2</sup><sub>p</sub>=0.37, large), Wake After Sleep Onset (p=0.042; η<sup>2</sup><sub>p</sub>=0.34, large), Immobility Time (p=0.005; η<sup>2</sup><sub>p</sub>=0.47, large) and Fragmentation Index (p=0.016; η<sup>2</sup><sub>p</sub>=0.36, large) displayed significant differences. In detail, Sleep Efficiency and Immobility Time significantly decreased at POST1 compared to PRE by 10.8% (p=0.003; ES: 0.9, moderate) and 9.4% (p=0.005; ES: 0.86, moderate) respectively. Overall, all sleep quality parameters showed a trend of constant improvement from POST1 to POST10. VAS scores were higher in the 1<sup>st</sup> day post-surgery (4.58 ± 2.46; p=0.0011 and ES: 1.40, large) compared to POST10 (1.68 ± 1.58) and in POST4 (3.85 ± 2.31) compared to POST10 (-2.18; p=0.0087 and ES: 1.09, moderate). During time, mean VAS showed significant negative correlations with mean Sleep Efficiency (r = -0.71; p=0.021) and mean Immobility Time (r = - 0.83; p=0.003) and a significant positive correlation with Fragmentation Index (r = 0.70; p=0.023), highlighting that high scores of pain were associated with lower overall sleep quality. <strong>Conclusion.</strong> Sleep quantity and timing parameters were stable during the entire hospitalization whereas sleep quality parameters significantly worsened the 1<sup>st</sup> night after surgery compared to the pre-surgery night and, overall, these parameters showed a trend of constant improvement until discharge. Pain scores were at the highest level the 1<sup>st</sup> day after surgery and at the lowest level before discharge with a negative correlation between pain and sleep quality parameters during time. The present study confirms the important impact of surgery on sleep parameters, especially on the first few post-operative days.</p>
Gene-based association analysis on 7 chronic pain types
<p>Gene-based association testing was run GCTA-fastBAT package on 7 phenotypes: chronic back, neck, hip, knee, facial, and abdominal pain and chronic headache. The summary statistics used to produce the text files required for this analysis have also been uploaded.</p>
Feasibility of using remotely delivered Spring Forest Qigong to reduce neuropathic pain in adults with spinal cord injury: A pilot study
<p class="mb15"><strong>Introduction:</strong> Approximately 69% of 299,000 Americans with spinal cord injury (SCI) suffer debilitating chronic neuropathic pain, which is intractable to treatment. The aim of this study is to determine feasibility, as the primary objective, and estimates of efficacy of a remotely delivered Qigong intervention in adults with SCI-related neuropathic pain, as the secondary objective.</p> <p class="mb15"><strong>Methods:</strong> We recruited adults with SCI-related neuropathic pain, with SCI ≥3 months, with complete or incomplete SCI, and highest neuropathic pain level of >3 on the Numeric Pain Rating Scale (NPRS), using nationwide volunteer sampling. Using a non-randomized controlled trial design, participants practiced Spring Forest Qigong's "Five Element Qigong Healing Movements" (online video) by combining movement to the best of their ability with kinesthetic imagery, at least 3x/week for 12 weeks. Adherence was automatically tracked through the Spring Forest Qigong website. Outcomes of neuropathic pain intensity (NPRS) were assessed weekly, and SCI-related symptoms were assessed at baseline, 6, and 12 weeks of Qigong practice and at 6-week and 1-year follow-ups.</p> <p class="mb15"><strong>Results:</strong> We recruited 23 adults with chronic SCI (7/2021–2/2023). In total, 18 participants started the study and completed all study components, including the 6-week follow-up. Twelve participants completed the 1-year follow-up assessment. Feasibility was demonstrated through participants' willingness to participate, adherence, and acceptability of the study. Mean age of the 18 participants was 60 ± 12 years, and they were 15 ± 11 years post-SCI with the highest baseline <em>neuropathic pain</em> of 7.94 ± 2.33, which was reduced to 4.17 ± 3.07 after 12 weeks of Qigong practice (Cohen's <em>d</em> = 1.75). This pain relief remained at 6-week and 1-year follow-ups. Participants reported reduced spasm frequency (change score 1.17 ± 1.20, <em>d</em> = 0.98) and severity (0.72 ± 1.02, <em>d</em> = 0.71), reduced interference of neuropathic pain on mood (3.44 ± 2.53, <em>d</em> = 1.36), sleep (3.39 ± 2.40, <em>d</em> = 1.41), daily activities (3.17 ± 2.77, <em>d</em> = 1.14), greater ability to perform functional activities (6.68 ± 3.07, <em>d</em> = 2.18), and improved mood (2.33 ± 3.31, <em>d</em> = 0.70) after Qigong.</p> <p class="mb15"><strong>Discussion:</strong> Remote Spring Forest Qigong's "Five Element Qigong Healing Movements" practice is feasible in adults with SCI-related neuropathic pain, with promising prolonged results of neuropathic pain relief and improvement in SCI-related symptoms after Qigong practice.</p> <p class="mb15"><strong>Clinical trial registration:</strong> <a href="https://www.clinicaltrials.gov/ct2/show/NCT04917107">https://www.clinicaltrials.gov/ct2/show/NCT04917107</a>, identifier NCT04917107</p>
Pathway enrichment of 5 chronic pain types
<p>Pathway enrichment analysis was performed on the phenotypes investigated in our study: chronic neck, back, hip and knee pain and chronic headaches. The VEGAS2Pathway tool was used.</p>
Exercise Application in the Treatment of Patients With Subacromial Pain Syndrome
ClinicalTrials.gov study NCT02695524. IPD Sharing: YES. Countries: 1. Publications: 15.
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
ClinicalTrials.gov study NCT00553280. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control
ClinicalTrials.gov study NCT04897841. IPD Sharing: NO. Countries: 1. Publications: 1.
Effect of Traction-Pressure-Release and Manual Pressure on Intramuscular Injection Pain
ClinicalTrials.gov study NCT07262463. IPD Sharing: NO. Countries: 1. Publications: 4.
Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management - Spinal Cord Injury
ClinicalTrials.gov study NCT03302793. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.